Sysmex’s income in Spain increases by 10%

Sysmex’s investment in Spain in the last three years has exceeded $10.7 million (10 million). During that period, the company has hired a hundred workers. The main lines of business of the company in the country are routine clinical tests: hematology, urinalysis, and flow cytometry. The company’s market share in Spain in this specialty is 32% and the forecast is to reach a market share of 45% in 2025.

Sysmex, the Spanish subsidiary of the Japanese health technology group specialized in in vitro diagnostics has closed the 2022 financial year with a turnover of $43 million (€40 million), which represents a growth of 10% compared to 2021, according to Arndt Knestel, general director of Sysmex in Spain and Portugal.

The company develops, manufactures, and sells equipment, reagents, and software necessary to perform diagnostic tests. Sysmex’s goal is to process more than 50 million tests in Spanish hospitals within two years, according to Knestel.

The company has been operating in Spain since 2010 and currently has more than 120 employees in the country. The company has expanded its activity into new diagnostic fields, among which the area of ​​hematology stands out.

Read more about Sysmex and find the best business news of the day with the Born2iNvets mobile app.

Sysmex employs more than 120 workers in Spain
Historically, the company has dedicated itself, in its area of ​​personalized medicine, to the diagnosis of breast cancer. Now, it also seeks to delve into endometrial, cervical, lung, and prostate cancer, among others. The company helps oncologists learn how to deal with a type of tumor, its stage, and the best treatment for the patient.

In Spain, the group has a sales channel and the business model is pay-per-use. In fact, the company has recently opened regional sales offices on Calle María de Molina in Madrid, beyond the facilities it already has in Sant Just Desvern (Barcelona).

Sysmex’s investment in Spain in the last three years has exceeded $10.7 million (10 million) and, also in that period, the company has hired a hundred workers. The main lines of business of the company in the country are routine clinical tests: hematology, urinalysis, and flow cytometry.

Hematology is a clinical specialty that dedicates its efforts to the study of the etiology, diagnosis, treatment, and prognosis of diseases that affect the production of blood and its components: leukocytes, erythrocytes, hemoglobin, and platelets. Urinalysis is an examination of a urine sample that can help identify medical problems such as kidney failure, diabetes, liver disease, and urinary tract infections.

The company’s market share in Spain in this specialty is 32% and the forecast is to reach a market share of 45% in 2025, according to Knestel. On the other hand, there is flow cytometry, which is a method of determining the number of cells, the percentage of living cells, and certain characteristics (such as size and shape) in a sample of blood, bone marrow, or other tissue.

Arndt Knestel has led the Spanish subsidiary of Sysmex since 2019
Knestel has led Sysmex in Spain since 2019, the year in which he joined the company. Previously, he worked for six years at Zeiss Medical Technology as CEO and for eleven years at Dräger, where he held the position of regional business controller.

The head of Sysmex in Spain has a degree in International Business Administration from the University of Economics and Business in Vienna and a degree in Business Administration from the University of Hagen. Knestel has an Executive Management Program from the St. Gallen Business School.

On a global scale, Sysmex operates in more than 190 countries and regions. In the area of ​​Europe, the Middle East, and Africa (EMEA) the company has more than 2,600 employees and its main business area is hematology. Born2Invest